Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRNA stock price vs A: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at A's multiple
Needs A P/S.
Implied fair value · at MRNA's multiple
Needs MRNA P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
AGILENT TECHNOLOGIES, INC. · implied price per share
Bear
$41.49
Base
$49.80
Bull
$60.61
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
MRNA vs PFE
JOHNSON & JOHNSON
MRNA vs JNJ
GILEAD SCIENCES, INC.
MRNA vs GILD
AMGEN INC
MRNA vs AMGN
NOVAVAX INC
MRNA vs NVAX
VERTEX PHARMACEUTICALS INC / MA
MRNA vs VRTX
THERMO FISHER SCIENTIFIC INC.
MRNA vs TMO
ILLUMINA, INC.
MRNA vs ILMN
BIO-TECHNE Corp
MRNA vs TECH
BRUKER CORP
MRNA vs BRKR
Azenta, Inc.
MRNA vs AZTA
WATERS CORP /DE/
MRNA vs WAT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRNA can re-accelerate revenue and materially improve operating leverage from the current -39.9% growth and -158.1% operating margin profile, then holding or buying may make sense because the stock is already embedded with a large A-based downside, but absent that turnaround the valuation looks stretched versus A.
MRNA’s current price of $59.17 implies a -50.6% downside to A-based implied price of $29.21, indicating a large valuation gap versus A. That gap is driven by MRNA’s much lower revenue base, negative earnings, and contracting growth despite a higher P/S multiple than A.
Supporting Metrics
